Conclusion: Tislelizumab combined with Axitinib as first-line treatment for intermediate-high risk metastatic ccRCC showed significant efficacy and manageable safety. (1)Histopathologically confirmed ...

"Without the dolphins, we would probably still be out there trying to clear those waterways," says ... then send the mammal back down to leave an acoustic transponder, which generated a pinging ...